Cannabidiol and Marihuana Research Expansion Act

Bill: 117-s-253
Sponsor: Sen. Feinstein, Dianne [D-CA]
Introduced: 2021-02-04 in the Senate
Policy area: Crime and Law Enforcement
Subjects: Congressional oversight
Drug safety, medical device, and laboratory regulation
Drug therapy
Drug trafficking and controlled substances
Drug, alcohol, tobacco use
Health personnel
Health programs administration and funding
Licensing and registrations
Medical research
Public-private cooperation
Research administration and funding
Trade restrictions

Summary:
action_date: 2021-02-04
text: 

Cannabidiol and Marihuana Research Expansion Act

 
This bill establishes a new, separate registration process to facilitate research on marijuana.
 
Specifically, the bill directs the Drug Enforcement Administration (DEA) to follow specified procedures to register (1) practitioners to conduct marijuana research, and (2) manufacturers to supply marijuana for the research.
 
The bill allows certain registered entities (including institutions of higher education, practitioners, and manufacturers) to manufacture, distribute, dispense, or possess marijuana or cannabidiol (CBD) for the purposes of medical research. Additionally, the bill directs the DEA to register manufacturers and distributors of CBD or marijuana for the purpose of commercial production of an approved drug that contains marijuana or its derivative.
 
Finally, the bill includes various other provisions, including provisions that
 
 
require the DEA to assess whether there is an adequate and uninterrupted supply of marijuana for research purposes;
 
prohibit the Department of Health and Human Services (HHS) from reinstating the interdisciplinary review process for marijuana research;
 
allow physicians to discuss the potential harms and benefits of marijuana and its derivatives (including CBD) with patients; and
 
require HHS, in coordination with the National Institutes of Health and relevant federal agencies, to report on the therapeutic potential of marijuana for various conditions such as epilepsy, as well as the impact on adolescent brains and on the ability to operate a motor vehicle.
 

action_date: 2022-03-24
text: 

Cannabidiol and Marihuana Research Expansion Act

 
This bill establishes a new, separate registration process to facilitate research on marijuana.
 
Specifically, the bill directs the Drug Enforcement Administration (DEA) to follow specified procedures to register (1) practitioners to conduct marijuana research, and (2) manufacturers to supply marijuana for the research.
 
The bill allows certain registered entities (including institutions of higher education, practitioners, and manufacturers) to manufacture, distribute, dispense, or possess marijuana or cannabidiol (CBD) for the purposes of medical research. Additionally, the bill directs the DEA to register manufacturers and distributors of CBD or marijuana for the purpose of commercial production of an approved drug that contains marijuana or its derivative.
 
Finally, the bill includes various other provisions, including provisions that
 
 
require the DEA to assess whether there is an adequate and uninterrupted supply of marijuana for research purposes;
 
prohibit the Department of Health and Human Services (HHS) from reinstating the interdisciplinary review process for marijuana research;
 
allow physicians to discuss the potential harms and benefits of marijuana and its derivatives (including CBD) with patients; and
 
require HHS, in coordination with the National Institutes of Health and relevant federal agencies, to report on the therapeutic potential of marijuana for various conditions such as epilepsy, as well as the impact on adolescent brains and on the ability to operate a motor vehicle.
 


Legislative actions:
action_date: 2022-03-28
text: Held at the desk.
action_date: 2022-03-28
text: Received in the House.
action_date: 2022-03-28
text: Message on Senate action sent to the House.
action_date: 2022-03-24
text: Passed Senate with an amendment by Unanimous Consent. (text of amendment in the nature of a substitute: CR S1781-1783)
action_date: 2022-03-24
text: Passed/agreed to in Senate: Passed Senate with an amendment by Unanimous Consent.(text of amendment in the nature of a substitute: CR S1781-1783)
action_date: 2022-03-24
text: Measure laid before Senate by unanimous consent. (consideration: CR S1784)
action_date: 2022-03-24
text: Senate Committee on the Judiciary discharged by Unanimous Consent.
action_date: 2022-03-24
text: Senate Committee on the Judiciary discharged by Unanimous Consent.
action_date: 2021-02-04
text: Read twice and referred to the Committee on the Judiciary. (Sponsor introductory remarks on measure: CR S477-478)
action_date: 2021-02-04
text: Introduced in Senate